Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HSK42360-Na with cetuximab with or without chemotherapy in BRAF V600-mutant metastatic colorectal cancer
CTR20262782Phase 2Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK42360-Na, cetuximab in colorectal adenocarcinoma, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Aug 2026; status: active.
02
Drugs
HSK42360-Nacetuximab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20262782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262782.